41 results about "Carcinoma bladder" patented technology

The FGFR-encoding gene was studied extensively with regard to its expression, hyperamplification, mutation, translocation, or such in various cancer cells. As a result, novel fusion polypeptides in which the FGFR3 polypeptide is fused with a different polypeptide were identified and isolated from several types of bladder cancer-derived cells and lung cancer cells. The use of a fusion polypeptide of the present invention as a biomarker in FGFR inhibitor-based cancer therapy enables one to avoid side effects in cancer therapy and control the therapeutic condition to produce the best therapeutic effect, thereby enabling individualized medicine.

The invention discloses an artemisinin derivative, a synthesis method and applications thereof. The artemisinin derivate is N-(3-N',N'-dimethylamino-propyl)-10-azadeoxyartemisinin, which is prepared by reacting artemisinin with N,N-dimethyl-1,3-diaminopropane and p-toluene sulfonic acid in sequence. By researching the proliferation inhibition activity of the derivative on multiple human tumor cell strains and human normal cell strains, the applicant finds that the derivative has a prominent proliferation inhibition activity on human bladder cancer cell T-24, human ovarian cancer cell SK-OV-3, and human stomach cancer cell MGC80-3, has a potential medicinal value, and can be used to prepare various antitumor drugs.

The invention discloses a newly discovered cancer promoting effect of DDX24 helicase, a method for realizing a cancer inhibition effect through point mutation and application of the DDX24 helicase. The contents of the invention comprise: 1, high expression of wild type DDX24 has significant correlation with tumor growth, and the growth of tumors can be promoted through high expression of the wildtype DDX24; 2, different from the mechanism of the pathogenic gene DDX24 for familial vascular malformation, DDX24 point mutation including K11E or E271K obviously inhibits the growth of tumors; 3, based on the new function and induced point mutation of DDX24 provided in the invention, a novel targeted therapy method can be provided for treatment of latent and refractory tumors, and a new thoughtcan also be provided for preparation of tumor-related vaccines; and 4, application of 1-3 described above is provided. The point mutation can be used for treating solid tumors including, but not limited to, squamous cell carcinoma of the head and the neck, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, skin melanoma, lymphoma, adenoma, thoracic adenoma, lung cancer, colorectal cancer, gallbladder cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, endometrial cancer, cervical cancer, nasopharyngeal cancer, bone cancer andmalignant myoma.

The present invention relates to a method for detecting c.-124 C>T and c.-146 C>T mutations in the Htert gene promoter. The method uses reaction compositions that comprise amplification primers and genotyping probes. Another aspect of this invention relates to the primers and probes used to implement the aforementioned method, with sequences, identified as SEQ ID no.1 to SEQ ID no.6, that displayhigh specificity for these mutations, and to the compositions containing these primers and probes. The present invention further relates to a kit comprising the above-mentioned compositions for detecting c.-124 C>T and c.-146 C>T mutations in the Htert gene promoter by carrying out the method according to the present invention. The method, gene sequences, compositions and kit of the present invention can be advantageously used for detecting trace amounts of c.-124 C>T and c.-146 C>T mutations in biological samples, due to their high sensitivity and specificity for such mutations. The present invention can thus be applied in early detection, identification, detection of recurrence or prediction and monitoring of diseases associated with this type of mutations, such as bladder carcinomas, thyroid carcinomas, squamous cell carcinomas, basal cell carcinomas, melanomas, gliomas and hepatocellular carcinomas, inter alia, and ultimately provide the basis for defining a suitable treatment. Thus, the present invention pertains to the technical fields of medicine, pharmaceutics, molecular biology, biochemistry, human genetics and the like.

The present invention provides a human low-invasive bladder cancer cell line, specifically, a new human low-invasive bladder cancer cell line CH‑1, which was preserved in the China Center for Type Culture Collection on August 26, 2013 ( CCTCC, China, Wuhan), the deposit number is CGMCC No.C2013128. The cell line of the present invention has stable cell morphology and passage characteristics, good tumorigenicity, and the cell line does not appear distant metastasis, can be used for the establishment of animal models, and can be used in combination with multi-organ metastatic bladder cancer cell lines for screening Drugs for different properties of bladder cancer, and for screening genes related to metastasis.

The invention relates to a group six dim carbocyclic ring azoles nucleoside analogues and their acceptable pharmaceutical compounds and their preparation methods and the application as antiviral and antineoplastic agents.The described compounds have varying degrees of inhibition effects on the human immunodeficiency virus replication and the replication of herpes virus; have varying degrees of inhibition on human lung cancer cell lines and human bladder cancer cell lines.

The invention provides an immune-enhancing antineoplastic collagen composition as well as a preparation method and an application thereof. The composition is characterized by consisting of antineoplastic factors, collagen, polysaccharide substances and active factors. The composition is applicable to, but not limited in, cells for treating breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostatic cancer, bladder cancer, melanoma, lung cancer, stomach cancer, liver cancer, head and neck squamous cell carcinoma, carcinoma of uterine cervix, renal cell carcinoma, thyroid cancer, acute myeloid leukemia, myeloma, esophageal squamous cancer, lymphoma and the like.

The invention provides a lentivirus-infected human bladder cancer cell line to knock out endogenous genes, and successfully establish a stable transfection cell line. Specifically, NPM1‑shRNA lentivirus infected T24 / DDP cell line to silence NPM1 (nucleolar phosphoprotein 1) expression, and successfully established T24 / DDP‑NPM1 ko cell line. The present invention confirms T24 / DDP-NPM1 through research ko Cell lines can be stably silenced NPM1 expression and passaged. T24 / DDP‑NPM1 after silencing NMP1 compared to negative control ko The expression level of NPM1 protein in the cell line was significantly decreased, the cell proliferation ability was significantly inhibited, the cell migration ability was increased, and the cell cycle was arrested in the S phase.

The present invention discloses a DC-CIK co-cultured cell, a preparation method thereof, a sensitizing antigen and an application thereof. The DC-CIK co-cultured cell is prepared by using separated mononuclear cells to be respectively induced and cultured into DC cells and CIK cells, wherein the DC cells are induced and stimulated by adding a self-constructed polypeptide sensitizing antigen whichis proven to be widely expressed in various tumor cells during a culture process, which can improve tumor killing effects. The DC-CIK co-cultured cell cultured by the method can have a very good killing effect on a variety of the tumor cells. Besides, the cultured DC-CIK cells have high activity and strong amplification ability, releases many cytokines of IFN-gamma, etc., and is strong in lethality. The co-cultured cell can be widely used in treatment of various cancers, including kidney cancers, prostate cancers, breast cancers, bladder cancers, melanoma, colon cancers, ovarian cancers, bonecancers, lung cancers, neuroblastoma, etc., and is wide in adaptive surfaces.

The invention discloses application of argyreia aceta alkali in biological medicines. The whole herb of argyreia aceta has medicinal value, and argyreia aceta is widely distributed in many places of Guangxi, such as Guigang, Yulin, Fangcheng Gang and Wuming, and is used as a traditional Chinese medicine for treating acute and chronic bronchitis, tuberculosis, liver cirrhosis, nephritis edema, sores and furuncles, acute mastitis, skin eczema, traumatic bleeding and other symptoms. The argyreia aceta alkali is a chemical component separated from argyreia aceta. According to the invention, through the tests for the proliferation inhibition effect of the argyreia aceta alkali on human lung adenocarcinoma cell H2228, human bladder cancer cell T24, human hepatoma carcinoma cell SMMC-7721, humanbreast cancer cell MCF-7, human gastric carcinoma cell MGC-803 and human oral squamous cell carcinoma Tca8113, the argyreia aceta alkali is found to have an excellent inhibiting effect on human bladder cancer cell T24 and human oral squamous cell carcinoma Tca8113 and has no obvious inhibiting effect on other tested tumor cells, so that the argyreia aceta alkali can be used for preparing drugs fortreating bladder cancer or oral squamous cell carcinoma.

The present invention provides a kind of no-cell Calmette-Guerin bacillus preparation, and medicine composition or mucosa immune regulator including the preparation. The no-cell Calmette-Guerin bacillus preparation is prepared through crushing and cracking Calmette-Guerin bacillus in a homogenating crushing process or ultrasonic crushing process. The preparation can strengthen immunological function of normal body, promote restoring of immunological function in hypoimmunity body and inhibit excessive immune response in hyperimmunity body, and has bidirectional immunological regulation. The preparation has obvious tumor inhibiting effect, can prevent cancers, and is one kind of safe and effective mucosa immune regulator.

The present invention relates to a novel regulatory T cell protein. The protein, named PD‑L3ORVISTA, resembles members of the PD‑L1 family and represents a novel and structurally distinct Ig superfamily inhibitory ligand whose ectodomain has the same identity as the B7 family ligand PD‑L1. source. This molecule is called PD‑L3OR VISTA or V-domain immunoglobulin inhibitor of T-cell activation (VISTA). The expression of VISTA is mainly localized in the hematopoietic compartment and is highly regulated on bone marrow APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway suggests a new approach to modulate T cell-mediated immunity for the treatment of various cancers such as ovarian, bladder and melanoma. Additionally, VISTA proteins, particularly multimeric VISTA proteins and antibodies are useful for suppressing T cell immunity in autoimmune diseases, allergies, infections and inflammatory disorders such as multiple sclerosis and joint disorders such as RA.

The invention discloses two ionic metal coordination compounds taking 9-aldehyde-10-pyrimidine anthracene hydrazone as a ligand, a synthesis method and applications thereof. The synthesis method comprises the following steps: carrying out a reaction on 9-aldehyde 10-(4',6'-dimethylpyrimidine) anthracene hydrazone and rhodium trichloride hydrate or iridium trichloride hydrate in a polar solvent under a heating condition to obtaining the ionic metal coordination compounds. The ionic metal coordination compounds disclosed by the invention have ionic type structures, and have low toxicity to humannormal hepatocytes and high inhibition activity to tumor cell strains, wherein especially the rhodium coordination compound has significant proliferation inhibition activity to human bladder cancer cells T-24 and human lung cancer cells NCI-H460, and has significantly high activity compared with cis-platinum, so that the rhodium coordination compound is expected to be developed into antitumor drugs.

The FGFR-encoding gene was studied extensively with regard to its expression, hyperamplification, mutation, translocation, or such in various cancer cells. As a result, novel fusion polypeptides in which the FGFR3 polypeptide is fused with a different polypeptide were identified and isolated from several types of bladder cancer-derived cells and lung cancer cells. The use of a fusion polypeptide of the present invention as a biomarker in FGFR inhibitor-based cancer therapy enables one to avoid side effects in cancer therapy and control the therapeutic condition to produce the best therapeutic effect, thereby enabling individualized medicine.